<DOC>
	<DOCNO>NCT02292823</DOCNO>
	<brief_summary>Prospective , non-randomized , single arm , multicenter observational study . The objective evaluate safety efficacy MGuard™ Prime stent treatment de novo stenotic lesion coronary artery patient undergo primary percutaneous coronary intervention ( PCI ) due acute ST elevation myocardial infarction ( STEMI ) real-world setting .</brief_summary>
	<brief_title>MGuard™ Prime Embolic Protection Stent Patients With Acute ST Elevation Myocardial Infarction</brief_title>
	<detailed_description />
	<mesh_term>Infarction</mesh_term>
	<mesh_term>Myocardial Infarction</mesh_term>
	<criteria>1 . Subject &gt; 18 year age . 2 . Subject experience clinical symptom consistent ST elevation acute myocardial infarction ( STEMI ) &gt; 30 minute &lt; 24 hour . 3 . Based coronary anatomy , primary PCI indicate culprit lesion anticipate use stenting . 4 . Subject agree require followup procedure visit provide informed consent require . 5 . The target lesion de novo lesion native coronary artery . 6 . The reference vessel diameter ( RVD ) infarct lesion 2.754.0 mm visual assessment . 1 . Subject undergoing cardiopulmonary resuscitation . 2 . Cardiogenic shock ( SBP &lt; 80 mmHg &gt; 30 minute , require IV pressor intraaortic balloon bump ( IABP ) hemodynamic support device hypotension ) . 3 . Comorbid condition ( ) others could limit subject 's ability participate trial comply followup requirement , impact scientific integrity trial . 4 . Target lesion involve bifurcation side branch &gt; /=2.0 mm diameter . 5 . In Investigator 's opinion lesion/vessel unsuitable treatment MGuard™ Prime Embolic Protection Stent System reason .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2015</verification_date>
	<keyword>STEMI</keyword>
	<keyword>heart attack</keyword>
	<keyword>stent</keyword>
	<keyword>Bare Metal Stent</keyword>
	<keyword>myocardial infarction</keyword>
	<keyword>PCI</keyword>
</DOC>